查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403382

神經內分泌腫瘤治療市場的全球市場預測（~2030）：治療方法、疾病狀態、給藥途徑、部位分析、最終用戶和區域進行分析

Neuroendocrine Tumor Treatment Market Forecasts to 2030 - Global Analysis By Service, Animal Model, Model Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

2023年全球神經內分泌腫瘤治療市場規模為25.872億美元，預計預測期內複合年成長率為15.7%，到2030年將達到71.807億美元。

神經內分泌腫瘤治療包括一系列旨在治療神經內分泌腫瘤（NET）的醫療干預措施，神經內分泌腫瘤是由神經內分泌細胞產生的一組不同的罕見腫瘤。這些腫瘤可發生在許多器官中，但最常發生在胰臟和消化器官系統。

根據國家轉化科學推進中心-遺傳和罕見疾病資訊中心2021年11月更新的資料，美國約有3,000至30,000人患有類癌，這種腫瘤通常發生在胃腸道或胃腸道。在肺部。

擴大神經內分泌腫瘤治療

患者數量的不斷增加促使製藥和生物技術公司投入資金進行研發，透過早期診斷和適當的干涉措施來改善患者的治療結果。診斷技術的改進、意識的提高、生活方式的改變以及透過分子分析進行的精準醫療等多種因素正在實現個體化治療策略並推動該市場的規模。

昂貴的治療費用

由於處方藥、醫療程序、住院和後續觀察護理的費用，患者可能難以負擔昂貴的治療費用，特別是如果他們負擔不起或沒有足夠的保險。治療神經內分泌腫瘤的高昂費用可能會使衛生系統難以分配足夠的資源，從而可能限制獲得這些基本治療方法並使這些基本治療方法變得更加難以負擔。此外，保險覆蓋範圍的差異和高額共付額進一步阻礙患者獲得最佳護理。

研發進度

分子分析已成為 NET 研究的一個重要方面，可以識別與這些腫瘤相關的特定生物標記和基因突變。這些發現導致了生長抑制素類似物、mTOR 抑制劑和胜肽受體放射性核素療法 (PRRT) 等創新治療方法的引入。此外，不斷的科學發現有助於更深入地了解分子機制和遺傳因素，最終改善患者預後並擴大可用治療方法的範圍，從而增加市場潛力。我們正在促進成長。

缺乏意識

神經內分泌腫瘤 (NET) 相對罕見，並且可能出現多種症狀，因此難以檢測。許多醫學相關人員對這些腫瘤知之甚少，這可能導致延誤診斷或誤診。此外，缺乏對 NET 的了解可能會導致對症狀的誤解和尋求醫療護理的延遲。這種認知的缺乏延伸到了更廣泛的醫學界，並可能導致 NET 病例的管理不理想。

COVID-19 的影響

神經內分泌腫瘤治療市場受到 COVID-19大流行的負面影響。醫療機構的關閉和能力有限導致神經內分泌腫瘤的檢測和治療延遲，影響了患者的治療結果。由於創新藥物的臨床試驗受到限制，資源和注意力都集中在應對這場流行病上，衛生服務的利用放緩。此外，對免疫抑制和醫療系統財政限制的擔憂也影響了開始和維持治療的意願，逐漸縮小了市場規模。

預計化療領域在預測期內將是最大的

化療部分估計佔最大佔有率。當手術和其他治療方法無效時，通常是在 NET 的晚期或轉移階段，通常會考慮化療。化療可以幫助控制症狀、減緩腫瘤生長並改善患者的生活品質，但治療並不總是有效。此外，正在研究有針對性的個人個體化化療方案，以減少神經內分泌腫瘤患者的副作用並改善治療結果，從而推動這一領域的擴張。

預計胰臟神經內分泌腫瘤部分在預測期內複合年成長率最高

預計胰臟神經內分泌腫瘤部分在預測期內複合年成長率最高。這些腫瘤起源於胰臟中的內分泌細胞，其獨特的特徵值得考慮專門治療。 pNET 的治療方法包括考慮腫瘤惡性、分期和功能等因素的多學科策略。此外，進行性或轉移性 pNET 的治療選擇包括生長抑制素類似物，可控制荷爾蒙相關症狀並抑制促進腫瘤生長的途徑，從而推動該部分的生長。

比最大的地區

由於 PET- 電腦斷層掃描和分子分析等先進診斷工具增強了神經內分泌腫瘤的早期檢測和表徵，預計亞太地區將在估計期間佔據最大的市場佔有率。標靶治療和免疫療法越來越受到關注，提供了更有效和個體化的治療選擇。此外，醫療保健相關人員、政府機構和製藥公司之間的合作對於解決這些差異和加強整體神經內分泌腫瘤治療至關重要，這正在推動該地區的成長。Masu。

複合年成長率最高的地區：

由於政府醫療保健政策和保險覆蓋範圍顯著影響患者獲得治療的機會，預計北美在預測期內將呈現最高的複合年成長率。由於該地區嚴格的監管以及醫療保健和研究方面的大規模公共和私人投資，禮來公司、諾華公司、和記黃埔醫藥有限公司和輝瑞公司等大公司正在良好的環境中發展。美國食品藥物管理局(FDA) 等監管機構在核准藥品和治療設備以確保安全性和有效性方面發揮核心作用，這推動了該地區的擴張。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球神經內分泌腫瘤治療市場：依治療方法分類

  • 化療
  • 標靶治療
  • 生長抑制素類似物
  • 免疫療法
  • 其他治療方法

第6章全球神經內分泌腫瘤治療市場：依疾病狀況

  • 胰臟神經內分泌腫瘤
  • 肺神經內分泌腫瘤
  • 胃腸道神經內分泌腫瘤
  • 其他醫療狀況

第7章全球神經內分泌腫瘤治療市場：依給藥途徑

  • 胃腸外的
  • 口服

第8章全球神經內分泌腫瘤治療市場：按地點分析

  • 冒號
  • 肺
  • 小腸
  • 胰臟
  • 其他站點分析

第9章全球神經內分泌腫瘤治療市場：依最終用戶分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 其他最終用戶

第10章全球神經內分泌腫瘤治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • Novartis AG
  • Exelixis, Inc.
  • Boehringer Ingelheim International GmbH
  • Tarveda Therapeutics
  • Dauntless Pharmaceuticals
  • Hutchison MediPharma Limited
  • AVEO Oncology
  • Pfizer Inc.
  • Ipsen Pharma
  • Progenics Pharmaceuticals, Inc.
  • Eli Lilly & Company
  • Lantheus Holdings, Inc.
  • Jubilant Life Sciences Ltd.
Product Code: SMRC24607

According to Stratistics MRC, the Global Neuroendocrine Tumor Treatment Market is accounted for $2,587.2 million in 2023 and is expected to reach $7,180.7 million by 2030 growing at a CAGR of 15.7% during the forecast period. Neuroendocrine tumor treatment encompasses a range of medical interventions aimed at managing neuroendocrine tumors (NETs), a diverse group of rare neoplasms that arise from neuroendocrine cells. These tumors can develop in a number of organs, although they most frequently affect the pancreas and digestive system.

According to the National Center for Advancing Translational Sciences - Genetic and Rare Diseases Information Center data updated in November 2021, there were around 3,000 to 30,000 people in the United States affected by carcinoid tumor, which usually develops in the gastrointestinal tract or the lungs.

Market Dynamics:

Driver:

Expansion of neuroendocrine tumor treatments

The growing number of patients has encouraged pharmaceutical and biotechnology businesses to spend money on research and development for better patient outcomes and appropriate interventions resulting from early diagnosis. Several factors including improved diagnostic techniques, greater awareness, and changes in lifestyle, precision medicine, guided by molecular profiling, allows for personalized therapeutic strategies, which are driving this market size.

Restraint:

High treatment costs

Patients may find it difficult to receive high-cost treatments, especially if they have limited financial resources or insufficient insurance, due to the expense of prescription drugs, medical procedures, hospital stays, and follow-up care. The high expense of treating neuroendocrine tumors may make it difficult for healthcare systems to devote enough funding, which could restrict the accessibility and affordability of these essential treatments. Furthermore, insurance coverage gaps and high out-of-pocket expenses further impede patient access to optimal treatment.

Opportunity:

Advancements in research developments

Molecular profiling has emerged as a key aspect of NET research, enabling the identification of specific biomarkers and genetic mutations associated with these tumors. These discoveries have led to the introduction of innovative treatment options such as somatostatin analogs, mTOR inhibitors, and peptide receptor radionuclide therapy (PRRT). Moreover, the ongoing scientific discoveries contribute to a deeper understanding of molecular mechanisms and genetic factors, ultimately enhancing patient outcomes and expanding the range of available treatments, thereby driving market growth.

Threat:

Lack of awareness

Neuroendocrine tumors (NETs) are difficult to detect since they are comparatively uncommon and present with a variety of symptoms. These tumors may not be well known to many medical professionals, which could cause delayed or incorrect diagnoses. Additionally, lack of knowledge on NETs, causes them to incorrectly interpret symptoms and delay seeking medical attention. This lack of awareness also extends to the broader medical community, potentially leading to suboptimal management of NET cases.

COVID-19 Impact

The market for neuroendocrine tumor treatments was adversely affected by the COVID-19 pandemic. Patient outcomes were impacted by delayed neuroendocrine tumor detection and treatment as a result of lockdowns and restricted capacity in healthcare facilities. Clinical trials for innovative medicines were restricted, and the availability of healthcare services was stretched due to the reallocation of resources and attention toward addressing the pandemic. Furthermore, concerns about immunosuppression and financial limitations on healthcare systems also affected the willingness to start or maintain therapy, gradually hindering the market size.

The chemotherapy segment is expected to be the largest during the forecast period

The chemotherapy segment is estimated to hold the largest share. Chemotherapy is typically considered in cases where surgery and other treatments are less effective, often in the advanced or metastatic stages of NETs. Chemotherapy can help control symptoms, reduce tumor growth, and enhance the patient's quality of life, but treatment is not always curative. Moreover, targeted and individualized chemotherapy regimens are being investigated in order to reduce side effects and improve treatment outcomes for people with neuroendocrine tumors, which is boosting this segment's expansion.

The pancreatic neuroendocrine tumor segment is expected to have the highest CAGR during the forecast period

The pancreatic neuroendocrine tumor segment is anticipated to have the highest CAGR during the forecast period. These tumors arise from the endocrine cells of the pancreas, and their distinct characteristics necessitate specialized treatment considerations. Treatment approaches for pNETs involve a multidisciplinary strategy, considering factors such as tumor grade, stage, and functionality. Additionally, for advanced or metastatic pNETs, therapeutic options include somatostatin analogs, which help control hormone-related symptoms and inhibit pathways promoting tumor growth, which are driving this segment's growth.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to advanced diagnostic tools, such as PET-CT scans and molecular profiling that have enhanced the early detection and characterization of neuroendocrine tumors. Targeted therapies and immunotherapies have gained prominence, offering more effective and personalized treatment options. Furthermore, collaborative efforts among healthcare stakeholders, government bodies, and pharmaceutical companies are crucial to addressing these disparities and enhancing the overall NET treatment, which is driving this region's growth.

Region with highest CAGR:

North America is expected to witness highest CAGR over the projection period, owing to government healthcare policies and insurance coverage that significantly influence patient access to these treatments. Key players such as Eli Lilly & Company, Novartis AG, Hutchison MediPharma Limited, and Pfizer Inc. are developing in a favorable environment due to the region's strict regulations and large public and private investments in healthcare and research. Regulatory bodies like the FDA (Food and Drug Administration) play a central role in drug and treatment device approvals, ensuring safety and efficacy, which are propelling this region's expansion.

Key players in the market:

Some of the key players in the Neuroendocrine Tumor Treatment Market include Novartis AG, Exelixis, Inc., Boehringer Ingelheim International GmbH, Tarveda Therapeutics, Dauntless Pharmaceuticals, Hutchison MediPharma Limited, AVEO Oncology, Pfizer Inc., Ipsen Pharma, Progenics Pharmaceuticals, Inc., Eli Lilly & Company, Lantheus Holdings, Inc. and Jubilant Life Sciences Ltd.

Key Developments:

In October 2023, Pfizer Inc. and BioNTech SE announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.

In August 2023, Novartis announced that it has completed its acquisition of Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases.

In July 2023, Eli Lilly and Company and Versanis Bio announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.

In July 2023, Flagship Pioneering, Inc. and Pfizer Inc. announced the companies have partnered to create a new pipeline of innovative medicines.

Therapies Covered:

  • Chemotherapy
  • Targeted Therapy
  • Somatostatin Analogues
  • Immunotherapy
  • Other Therapies

Disease Indications Covered:

  • Pancreatic Neuroendocrine Tumor
  • Lung Neuroendocrine Tumor
  • Gastrointestinal Neuroendocrine Tumor
  • Other Disease Indications

Route of Administrations Covered:

  • Parenteral
  • Oral

Site Analysis Covered:

  • Colon
  • Lungs
  • Small Intestine
  • Pancreas
  • Other Site Analysis

End Users Covered:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neuroendocrine Tumor Treatment Market, By Therapy

  • 5.1 Introduction
  • 5.2 Chemotherapy
  • 5.3 Targeted Therapy
  • 5.4 Somatostatin Analogues
  • 5.5 Immunotherapy
  • 5.6 Other Therapies

6 Global Neuroendocrine Tumor Treatment Market, By Disease Indication

  • 6.1 Introduction
  • 6.2 Pancreatic Neuroendocrine Tumor
  • 6.3 Lung Neuroendocrine Tumor
  • 6.4 Gastrointestinal Neuroendocrine Tumor
  • 6.5 Other Disease Indications

7 Global Neuroendocrine Tumor Treatment Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Parenteral
  • 7.3 Oral

8 Global Neuroendocrine Tumor Treatment Market, By Site Analysis

  • 8.1 Introduction
  • 8.2 Colon
  • 8.3 Lungs
  • 8.4 Small Intestine
  • 8.5 Pancreas
  • 8.6 Other Site Analysis

9 Global Neuroendocrine Tumor Treatment Market, By End User

  • 9.1 Introduction
  • 9.2 Hospital Pharmacy
  • 9.3 Online Pharmacy
  • 9.4 Retail Pharmacy
  • 9.5 Other End Users

10 Global Neuroendocrine Tumor Treatment Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Novartis AG
  • 12.2 Exelixis, Inc.
  • 12.3 Boehringer Ingelheim International GmbH
  • 12.4 Tarveda Therapeutics
  • 12.5 Dauntless Pharmaceuticals
  • 12.6 Hutchison MediPharma Limited
  • 12.7 AVEO Oncology
  • 12.8 Pfizer Inc.
  • 12.9 Ipsen Pharma
  • 12.10 Progenics Pharmaceuticals, Inc.
  • 12.11 Eli Lilly & Company
  • 12.12 Lantheus Holdings, Inc.
  • 12.13 Jubilant Life Sciences Ltd.

List of Tables

  • Table 1 Global Neuroendocrine Tumor Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 3 Global Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 4 Global Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 5 Global Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2021-2030) ($MN)
  • Table 6 Global Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 7 Global Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 8 Global Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 9 Global Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 10 Global Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 11 Global Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 12 Global Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 13 Global Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 14 Global Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 15 Global Neuroendocrine Tumor Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 16 Global Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2021-2030) ($MN)
  • Table 17 Global Neuroendocrine Tumor Treatment Market Outlook, By Colon (2021-2030) ($MN)
  • Table 18 Global Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2021-2030) ($MN)
  • Table 19 Global Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2021-2030) ($MN)
  • Table 20 Global Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2021-2030) ($MN)
  • Table 21 Global Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2021-2030) ($MN)
  • Table 22 Global Neuroendocrine Tumor Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 23 Global Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 24 Global Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 25 Global Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 26 Global Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 27 North America Neuroendocrine Tumor Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 28 North America Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 29 North America Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 30 North America Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 31 North America Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2021-2030) ($MN)
  • Table 32 North America Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 33 North America Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 34 North America Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 35 North America Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 36 North America Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 37 North America Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 38 North America Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 39 North America Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 40 North America Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 41 North America Neuroendocrine Tumor Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 42 North America Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2021-2030) ($MN)
  • Table 43 North America Neuroendocrine Tumor Treatment Market Outlook, By Colon (2021-2030) ($MN)
  • Table 44 North America Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2021-2030) ($MN)
  • Table 45 North America Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2021-2030) ($MN)
  • Table 46 North America Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2021-2030) ($MN)
  • Table 47 North America Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2021-2030) ($MN)
  • Table 48 North America Neuroendocrine Tumor Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 49 North America Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 50 North America Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 51 North America Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 52 North America Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 53 Europe Neuroendocrine Tumor Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 54 Europe Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 55 Europe Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 56 Europe Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 57 Europe Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2021-2030) ($MN)
  • Table 58 Europe Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 59 Europe Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 60 Europe Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 61 Europe Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 62 Europe Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 63 Europe Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 64 Europe Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 65 Europe Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 66 Europe Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 67 Europe Neuroendocrine Tumor Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 68 Europe Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2021-2030) ($MN)
  • Table 69 Europe Neuroendocrine Tumor Treatment Market Outlook, By Colon (2021-2030) ($MN)
  • Table 70 Europe Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2021-2030) ($MN)
  • Table 71 Europe Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2021-2030) ($MN)
  • Table 72 Europe Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2021-2030) ($MN)
  • Table 73 Europe Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2021-2030) ($MN)
  • Table 74 Europe Neuroendocrine Tumor Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 75 Europe Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 76 Europe Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 77 Europe Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 78 Europe Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 79 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 80 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 81 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 82 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 83 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2021-2030) ($MN)
  • Table 84 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 85 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 86 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 87 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 88 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 89 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 90 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 91 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 92 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 93 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 94 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2021-2030) ($MN)
  • Table 95 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Colon (2021-2030) ($MN)
  • Table 96 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2021-2030) ($MN)
  • Table 97 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2021-2030) ($MN)
  • Table 98 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2021-2030) ($MN)
  • Table 99 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2021-2030) ($MN)
  • Table 100 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 101 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 102 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 103 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 104 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 105 South America Neuroendocrine Tumor Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 106 South America Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 107 South America Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 108 South America Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 109 South America Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2021-2030) ($MN)
  • Table 110 South America Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 111 South America Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 112 South America Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 113 South America Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 114 South America Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 115 South America Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 116 South America Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 117 South America Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 118 South America Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 119 South America Neuroendocrine Tumor Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 120 South America Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2021-2030) ($MN)
  • Table 121 South America Neuroendocrine Tumor Treatment Market Outlook, By Colon (2021-2030) ($MN)
  • Table 122 South America Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2021-2030) ($MN)
  • Table 123 South America Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2021-2030) ($MN)
  • Table 124 South America Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2021-2030) ($MN)
  • Table 125 South America Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2021-2030) ($MN)
  • Table 126 South America Neuroendocrine Tumor Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 127 South America Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 128 South America Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 129 South America Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 130 South America Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 131 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 132 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 133 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 134 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 135 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2021-2030) ($MN)
  • Table 136 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 137 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 138 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 139 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 140 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 141 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 142 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 143 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 144 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 145 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 146 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2021-2030) ($MN)
  • Table 147 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Colon (2021-2030) ($MN)
  • Table 148 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2021-2030) ($MN)
  • Table 149 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2021-2030) ($MN)
  • Table 150 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2021-2030) ($MN)
  • Table 151 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2021-2030) ($MN)
  • Table 152 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 153 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 154 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 155 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 156 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2021-2030) ($MN)